<mxfile host="app.diagrams.net">
  <diagram name="Weldon-MedicinalChemistry" id="weldon-main">
    <mxGraphModel dx="2200" dy="1400" grid="1" gridSize="10" guides="1" tooltips="1" connect="1" arrows="1" fold="1" page="1" pageScale="1" pageWidth="1600" pageHeight="1400">
      <root>
        <mxCell id="0" />
        <mxCell id="1" parent="0" />

        <!-- TITLE -->
        <mxCell id="title" value="MEDICINAL CHEMISTRY - Dr. Weldon&#xa;BPH/ED/UI Drug Structures | Osteoporosis Drug Chemistry | Gonadal Hormones SAR" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontStyle=1;fontSize=18;align=center;verticalAlign=middle;" vertex="1" parent="1">
          <mxGeometry x="40" y="20" width="1520" height="80" as="geometry" />
        </mxCell>

        <!-- ========== SECTION 1: BPH & ED MED CHEM ========== -->
        <mxCell id="male-section" value="BPH & ED MEDICINAL CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#dae8fc;strokeColor=#6c8ebf;fontStyle=1;fontSize=16;" vertex="1" parent="1">
          <mxGeometry x="40" y="130" width="500" height="50" as="geometry" />
        </mxCell>

        <!-- Alpha-1 Antagonists -->
        <mxCell id="alpha-box" value="ALPHA-1 ANTAGONISTS (BPH)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#cfe2f3;strokeColor=#6c8ebf;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="60" y="210" width="220" height="40" as="geometry" />
        </mxCell>

        <mxCell id="alpha-structure" value="Core Structure: QUINAZOLINE&#xa;Suffix: -AZOSIN&#xa;&#xa;Key Groups:&#xa;• Sulfonamide (essential)&#xa;• Piperazine/piperidine ring&#xa;• Methoxy substituents" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" vertex="1" parent="1">
          <mxGeometry x="60" y="265" width="220" height="130" as="geometry" />
        </mxCell>

        <mxCell id="tamsulosin-sar" value="Tamsulosin (Flomax)&#xa;• Selective for alpha-1A&#xa;  (prostate > vasculature)&#xa;• LESS orthostatic hypotension&#xa;• Sulfonamide + benzene ring" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="60" y="410" width="220" height="100" as="geometry" />
        </mxCell>

        <mxCell id="doxazosin-sar" value="Doxazosin (Cardura)&#xa;• NON-selective alpha-1&#xa;• Quinazoline core&#xa;• Used for BPH + HTN&#xa;• MORE hypotension risk" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="60" y="525" width="220" height="95" as="geometry" />
        </mxCell>

        <!-- 5-ARIs -->
        <mxCell id="5ari-box" value="5-ALPHA-REDUCTASE INHIBITORS" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#cfe2f3;strokeColor=#6c8ebf;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="310" y="210" width="210" height="40" as="geometry" />
        </mxCell>

        <mxCell id="5ari-structure" value="Both are STEROIDAL&#xa;4-Azasteroid structure&#xa;(mimic testosterone)&#xa;&#xa;Isoforms:&#xa;• Type 1: Skin/liver&#xa;• Type 2: Reproductive tissue" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" vertex="1" parent="1">
          <mxGeometry x="310" y="265" width="210" height="130" as="geometry" />
        </mxCell>

        <mxCell id="finasteride-sar" value="Finasteride (Proscar)&#xa;• Type 2 SELECTIVE&#xa;• 30x more selective for type 2&#xa;• t1/2: 6 hours&#xa;• Used: BPH, male pattern baldness" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="310" y="410" width="210" height="100" as="geometry" />
        </mxCell>

        <mxCell id="dutasteride-sar" value="Dutasteride (Avodart)&#xa;• Inhibits BOTH Type 1 + 2&#xa;• 10x more potent for type 2&#xa;• t1/2: 5 WEEKS (very long)&#xa;• More complete DHT suppression" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="310" y="525" width="210" height="95" as="geometry" />
        </mxCell>

        <!-- PDE5 Inhibitors -->
        <mxCell id="pde5-box" value="PDE5 INHIBITORS (ED)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#cfe2f3;strokeColor=#6c8ebf;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="60" y="660" width="220" height="40" as="geometry" />
        </mxCell>

        <mxCell id="pde5-structure" value="Core: PYRAZOLOPYRIMIDINONE&#xa;&#xa;Key Features:&#xa;• Based on GUANINE (mimic GMP)&#xa;• Sulfonamide for water solubility&#xa;• Competitive inhibitors&#xa;&#xa;SELECTIVITY vs POTENCY:&#xa;• Selectivity = 1 drug, multiple targets&#xa;• Potency = multiple drugs, 1 target" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" vertex="1" parent="1">
          <mxGeometry x="60" y="715" width="220" height="170" as="geometry" />
        </mxCell>

        <mxCell id="sildenafil-sar" value="Sildenafil (Viagra)&#xa;• Only >10-fold PDE5 vs PDE6&#xa;• PDE6 in retina → BLUE VISION&#xa;• Poor selectivity = side effects" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="60" y="900" width="220" height="80" as="geometry" />
        </mxCell>

        <mxCell id="pde5-better" value="Tadalafil, Vardenafil, Avanafil:&#xa;• Better PDE5/PDE6 selectivity&#xa;• Fewer visual side effects&#xa;• Same core structure with&#xa;  modifications for selectivity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="60" y="995" width="220" height="95" as="geometry" />
        </mxCell>

        <!-- ========== SECTION 2: UI & OSTEOPOROSIS MED CHEM ========== -->
        <mxCell id="ui-bone-section" value="URINARY INCONTINENCE & OSTEOPOROSIS CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5e8d4;strokeColor=#82b366;fontStyle=1;fontSize=16;" vertex="1" parent="1">
          <mxGeometry x="580" y="130" width="500" height="50" as="geometry" />
        </mxCell>

        <!-- UI Drugs -->
        <mxCell id="ui-box" value="URINARY INCONTINENCE DRUGS" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="600" y="210" width="220" height="40" as="geometry" />
        </mxCell>

        <mxCell id="antimuscarinics-sar" value="Antimuscarinics (M3 blockers)&#xa;• Structurally resemble&#xa;  ACETYLCHOLINE&#xa;• Competitive antagonists&#xa;&#xa;Examples:&#xa;• Oxybutynin, Tolterodine&#xa;• Tertiary amines&#xa;• Cross BBB → CNS effects" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="600" y="265" width="220" height="145" as="geometry" />
        </mxCell>

        <mxCell id="beta3-sar" value="Beta-3 Agonists&#xa;• Structurally resemble&#xa;  EPINEPHRINE&#xa;• Selective for beta-3 receptors&#xa;&#xa;Mirabegron (Myrbetriq):&#xa;• Phenylethylamine core&#xa;• NO anticholinergic SE" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="600" y="425" width="220" height="130" as="geometry" />
        </mxCell>

        <mxCell id="ddavp-sar" value="Desmopressin (DDAVP)&#xa;• Vasopressin analogue&#xa;• Modified for oral bioavailability&#xa;• Longer duration than vasopressin&#xa;• Used for nocturia/nocturnal&#xa;  polyuria" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="600" y="570" width="220" height="115" as="geometry" />
        </mxCell>

        <!-- Bisphosphonates -->
        <mxCell id="bpp-box" value="BISPHOSPHONATES" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="850" y="210" width="210" height="40" as="geometry" />
        </mxCell>

        <mxCell id="bpp-structure" value="Mimic INORGANIC PYROPHOSPHATE&#xa;&#xa;Key Innovation: P-C-P bond&#xa;(vs P-O-P in IPP)&#xa;→ Resistant to hydrolysis&#xa;→ Long half-life&#xa;&#xa;R1: Variable (OH, H, Cl)&#xa;R2: Side chain determines potency" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" vertex="1" parent="1">
          <mxGeometry x="850" y="265" width="210" height="160" as="geometry" />
        </mxCell>

        <mxCell id="bpp-r2" value="R2 Side Chain Effects:&#xa;&#xa;Simple alkyl (etidronate):&#xa;• Less potent&#xa;&#xa;Nitrogen-containing:&#xa;• MUCH more potent&#xa;• ↑ BRONJ risk&#xa;• Alendronate, Risedronate,&#xa;  Zoledronate" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="850" y="440" width="210" height="155" as="geometry" />
        </mxCell>

        <mxCell id="zoledronate-sar" value="Zoledronate (Reclast)&#xa;• Most potent bisphosphonate&#xa;• Two nitrogen atoms&#xa;• IV administration only&#xa;• Annual dosing" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="850" y="610" width="210" height="95" as="geometry" />
        </mxCell>

        <!-- PTH Analogues -->
        <mxCell id="pth-box" value="PTH ANALOGUES (Anabolic)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="600" y="730" width="220" height="40" as="geometry" />
        </mxCell>

        <mxCell id="pth-sar" value="Teriparatide (Forteo)&#xa;• Recombinant PTH (1-34)&#xa;• NOT antiresorptive&#xa;• ANABOLIC: ↑ osteoblast activity&#xa;&#xa;Theory: Build more bone than&#xa;you lose (net formation)&#xa;&#xa;Abaloparatide: Similar mechanism" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="600" y="785" width="220" height="155" as="geometry" />
        </mxCell>

        <!-- Monoclonal Antibodies -->
        <mxCell id="mab-box" value="MONOCLONAL ANTIBODIES" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="850" y="730" width="210" height="40" as="geometry" />
        </mxCell>

        <mxCell id="denosumab-sar" value="Denosumab (Prolia)&#xa;• Binds RANKL&#xa;• Prevents osteoclast&#xa;  differentiation&#xa;• Antiresorptive mechanism&#xa;• SC q6 months" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="850" y="785" width="210" height="105" as="geometry" />
        </mxCell>

        <mxCell id="romosozumab-sar" value="Romosozumab (Evenity)&#xa;• Anti-sclerostin antibody&#xa;• DUAL MOA (UNIQUE):&#xa;  1. ↑ Bone formation&#xa;  2. ↓ Bone resorption&#xa;• CV contraindications limit use" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f3e5f5;strokeColor=#9673a6;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="850" y="905" width="210" height="120" as="geometry" />
        </mxCell>

        <!-- ========== SECTION 3: GONADAL HORMONES SAR ========== -->
        <mxCell id="hormone-section" value="GONADAL HORMONES MEDICINAL CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f8cecc;strokeColor=#b85450;fontStyle=1;fontSize=16;" vertex="1" parent="1">
          <mxGeometry x="1120" y="130" width="440" height="50" as="geometry" />
        </mxCell>

        <!-- Estrogens -->
        <mxCell id="estrogen-box" value="ESTROGEN CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="1140" y="210" width="190" height="40" as="geometry" />
        </mxCell>

        <mxCell id="estrogen-class" value="Classification: C18 Steroid&#xa;• AROMATIC A-ring (essential)&#xa;• 3-Phenolic OH (essential)&#xa;• 17β-OH for maximal potency&#xa;&#xa;Classic estrogens:&#xa;• Estrone (E1)&#xa;• 17β-Estradiol (E2 - most potent)&#xa;• Estriol (E3)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="1140" y="265" width="190" height="170" as="geometry" />
        </mxCell>

        <mxCell id="ee-sar" value="Ethinyl Estradiol (EE)&#xa;• 17α-ETHINYL blocks metabolism&#xa;• Prevents estrone conversion&#xa;• 15-20x more potent orally&#xa;• Used in ALL oral contraceptives&#xa;&#xa;Mestranol:&#xa;• 3-O-methyl PRODRUG of EE" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="1140" y="450" width="190" height="145" as="geometry" />
        </mxCell>

        <!-- Aromatase -->
        <mxCell id="aromatase-box" value="AROMATASE (CYP19)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="1140" y="620" width="190" height="40" as="geometry" />
        </mxCell>

        <mxCell id="aromatase-sar" value="Critical Enzyme:&#xa;• Converts androgens → estrogens&#xa;• Requires 3 O2 + NADPH&#xa;&#xa;Aromatase Inhibitors:&#xa;• Anastrozole, Letrozole&#xa;• Nonsteroidal triazoles&#xa;• N-4 azole binds HEME IRON&#xa;• Prevents O2 binding&#xa;• Block estrogen synthesis" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="1140" y="675" width="190" height="175" as="geometry" />
        </mxCell>

        <!-- Progestins -->
        <mxCell id="progestin-box" value="PROGESTIN CHEMISTRY" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontStyle=1;fontSize=13;" vertex="1" parent="1">
          <mxGeometry x="1360" y="210" width="180" height="40" as="geometry" />
        </mxCell>

        <mxCell id="progestin-class" value="Classification: C21 Steroid&#xa;• 3-Keto-4,5-ene structure&#xa;&#xa;Progesterone:&#xa;• Rapid metabolism (t1/2 5-10 min)&#xa;• Poor oral bioavailability&#xa;→ Synthetic progestins needed" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="1360" y="265" width="180" height="135" as="geometry" />
        </mxCell>

        <mxCell id="pregnane-sar" value="PREGNANES:&#xa;• C6 methyl → oral availability&#xa;• Medroxyprogesterone&#xa;• No androgenic activity&#xa;&#xa;19-NORANDROSTANES:&#xa;• From testosterone&#xa;• Loss of C19 methyl → ↓ androgenic" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="1360" y="415" width="180" height="145" as="geometry" />
        </mxCell>

        <mxCell id="ethinyl-progestin" value="KEY SAR PRINCIPLE:&#xa;&#xa;ETHINYL on ANDROGEN&#xa;→ Converts to PROGESTIN&#xa;&#xa;Examples:&#xa;• Norethindrone (NET)&#xa;• Levonorgestrel (LNG - high&#xa;  androgenic)&#xa;• Norgestimate, Desogestrel&#xa;  (3rd gen - low androgenic)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;fontStyle=1;" vertex="1" parent="1">
          <mxGeometry x="1360" y="575" width="180" height="180" as="geometry" />
        </mxCell>

        <mxCell id="sprm-box" value="SPRM: Ulipristal (Ella)&#xa;• Selective Progesterone Receptor&#xa;  Modulator&#xa;• Emergency contraception&#xa;• Within 120 hours (5 days)&#xa;&#xa;Mifepristone (RU-486):&#xa;• Progesterone antagonist&#xa;• Medical abortion" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;align=left;fontSize=11;" vertex="1" parent="1">
          <mxGeometry x="1360" y="770" width="180" height="145" as="geometry" />
        </mxCell>

        <!-- ========== HIGH-YIELD MED CHEM PEARLS ========== -->
        <mxCell id="pearls-box" value="HIGH-YIELD MED CHEM PEARLS" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontStyle=1;fontSize=14;" vertex="1" parent="1">
          <mxGeometry x="40" y="1130" width="1520" height="40" as="geometry" />
        </mxCell>

        <mxCell id="pearl1" value="Quinazoline +&#xa;-azosin suffix =&#xa;Alpha-1 antagonist" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="60" y="1190" width="140" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl2" value="Both 5-ARIs are&#xa;STEROIDAL&#xa;(4-azasteroid)" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="220" y="1190" width="140" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl3" value="PDE5 inhibitors:&#xa;Guanine-based,&#xa;mimic GMP" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="380" y="1190" width="140" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl4" value="Antimuscarinics&#xa;resemble&#xa;acetylcholine" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="540" y="1190" width="140" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl5" value="BPPs: P-C-P bond&#xa;vs P-O-P in IPP&#xa;= resistant to hydrolysis" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="700" y="1190" width="150" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl6" value="Nitrogen-containing&#xa;R2 in BPPs:&#xa;↑ potency + ↑ BRONJ" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="870" y="1190" width="150" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl7" value="17α-Ethinyl:&#xa;Blocks metabolism&#xa;→ oral activity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="1040" y="1190" width="140" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl8" value="Aromatase inhibitors:&#xa;Azole binds heme&#xa;iron of CYP19" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="1200" y="1190" width="150" height="70" as="geometry" />
        </mxCell>

        <mxCell id="pearl9" value="19-Nor: Loss of&#xa;C19 methyl → ↓&#xa;androgenic activity" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=11;fontStyle=1;align=center;" vertex="1" parent="1">
          <mxGeometry x="1370" y="1190" width="170" height="70" as="geometry" />
        </mxCell>

        <!-- Legend -->
        <mxCell id="legend-box" value="LEGEND" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f5f5f5;strokeColor=#666666;fontStyle=1;fontSize=12;" vertex="1" parent="1">
          <mxGeometry x="40" y="1300" width="1520" height="30" as="geometry" />
        </mxCell>

        <mxCell id="legend1" value="Blue = Male/BPH/ED drugs" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#dae8fc;strokeColor=#6c8ebf;fontSize=10;" vertex="1" parent="1">
          <mxGeometry x="60" y="1345" width="180" height="30" as="geometry" />
        </mxCell>

        <mxCell id="legend2" value="Pink = Female/hormone drugs" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#f8cecc;strokeColor=#b85450;fontSize=10;" vertex="1" parent="1">
          <mxGeometry x="260" y="1345" width="180" height="30" as="geometry" />
        </mxCell>

        <mxCell id="legend3" value="Purple = Bone/osteoporosis" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#e1d5e7;strokeColor=#9673a6;fontSize=10;" vertex="1" parent="1">
          <mxGeometry x="460" y="1345" width="180" height="30" as="geometry" />
        </mxCell>

        <mxCell id="legend4" value="Green = Urinary/general" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#d5e8d4;strokeColor=#82b366;fontSize=10;" vertex="1" parent="1">
          <mxGeometry x="660" y="1345" width="180" height="30" as="geometry" />
        </mxCell>

        <mxCell id="legend5" value="Orange = SAR/structural features" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#ffe6cc;strokeColor=#d79b00;fontSize=10;" vertex="1" parent="1">
          <mxGeometry x="860" y="1345" width="200" height="30" as="geometry" />
        </mxCell>

        <mxCell id="legend6" value="Light blue = Individual drugs" style="rounded=1;whiteSpace=wrap;html=1;fillColor=#b3d9ff;strokeColor=#6c8ebf;fontSize=10;" vertex="1" parent="1">
          <mxGeometry x="1080" y="1345" width="180" height="30" as="geometry" />
        </mxCell>

      </root>
    </mxGraphModel>
  </diagram>
</mxfile>
